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ABSTRACT 
We investigated the potential of an extract of 
Lycopodium obscurum L.; 
stigmastane-3-oxo-21-oic acid (SA), to enhance 
osteogensis of mouse osteoblastic MC3T3-E1 
cells. SA at a concentration of 16 µM was found 
to have no significant effect upon the viability of 
the cells, thus concentrations of 8 µM and 16 µM 
of SA were used in all further experiments. Both 
concentrations of SA had an inhibitory affect 
upon alkaline phosphatase activity (ALP) after 8 
days incubation, however, after 16 days activity 
was restored to control levels. However Alizarin 
red S staining showed increased levels of min-
eralization for both concentrations after 16 days 
culture. Real time PCR showed inhibition of 
genes Runx2 and Osterix genes responsible for 
the up-regulation of ALP. However early time 
point (8 days) up-regulation of bone matrix 
mineralization genes OPN and OCN, and late 
time point (16 days) up-regulation of both Jun-D 
and Fra-2 mRNA expression was significantly 
enhanced. These results suggest a potential 
mechanism of SA in enhancing bone fracture 
healing is through the up-regulating bone ma-
trix mineralization. 
 
Keywords: Osteogenesis, RT-PCR 
1. INTRODUCTION 
Lycopodium obscurum L.; also known as Shen Jin 
Cao in China and ground pine in the USA, is a plant 
widely distributed in Hubei, Sichuan, Guizhou and Ti-
bet in China. It has long been used in traditional Chi-
nese medicine and traditional Tu medicine to treat ar-
thritis pain, quadriplegia, dysmenorrheal and contusion 
[1]. It is also used in treatment of bone fractures [2-3]. 
However, little is known about the pharmacology of 
Lycopodium obscurum L. in bone fracture healing, 
which prevents its application in western medical prac-
tices. 
The Lycopodium family is rich in alkaloids which 
have been reported to have strong bioactivity [4]. Cur-
rently more than 200 alkaloids and 140 serratane-type 
triterpenoids have been isolated from Lycopodium ge-
nus and theraputical effects (including an-
ti-inflammation, analgetic and antibiosis, etc) of some 
of these chemicals have been identified [5-6]. However, 
limited information is available on the chemical com-
pounds isolated from Lycopodium obscurum L. and any 
associated theraputical value. Recently, a series of nov-
el compounds have been isolated from Lycopodium 
obscurum L. These compounds include two new 
onoceranoid triterpenoids, 
(3α,8β,14α,21β)-26,27-dinoronocerane-3,8,14,21-tertro
l and 26-nor-8β-hydroxy-α-onocerin [7] and 
stigmastane-3-oxo-21-oic acid (SA) (unpublished). 
Since Lycopodium obscurum L. has a long history of 
use in bone fracture healing in traditional Chinese 
Medicine, this study focused on identifying whether 
one of the isolated compounds, SA, could demonstrate 
osteogenic potential. 
Developmental osteogenesis in vivo is a complex se-
ries of events involving a preosteoblast differentiation 
stage; the differentiation of MSC cells into osteoblast 
lineage. This stage is controlled in part, by two key 
genes, Runx2 and Osterix (OTX), expressed during 
osteoprogeniter cell differentiation towards osteoblasts. 
The bone matrix formation stage, which includes the 
expression of bone-related genes such as; alkaline 
phosphatase (ALP), type I collagen (COL1), 
osteopontin (OPN), osteonectin (SPARC), osteocalcin 
(OCN) and bone sialoprotein (IBSP), follows the 
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preosteoblast differentiation stage. This is followed by 
the bone matrix mineralization phase. 
Bone-related genes play a key role in the formation 
of the osseous matrix and matrix calcification [8-9]. 
Runx2 binds to the promoter of osterix and up-regulate 
its expression [10]. OTX, a specific transcription factor 
found in osteoblasts, is only expressed in developing 
bone tissue, its expression is required during stem cell 
differentiation toward the osteoblast lineage [11-12]. 
The genes c-jun, c-fos, JunD, Fra-1 and Fra-2 belong to 
the Ap-1 family, a transcription factor family expressed 
during the bone mineralization stage. ALP is a marker 
of early bone matrix formation [13-14], and is believed 
to be involved in the decomposition of organic phos-
phate-containing compounds to provide the phosphate 
needed during bone mineralization [15]. 
The aim of this study was to investigate the potential 
of the isolated compound stigmastane-3-oxo-21-oic 
acid (SA) from Lycopodium obscurum L. to induce 
bone formation. Firstly this study aimed to determine 
any harmful effect SA potentially had upon cells in 
culture by a viability assay, and established working 
concentrations. These concentrations will be tested for 
both ALP activity and mineralization. Finally real time 
PCR will be used to assess expression of key genes 
responsible for bone formation, early osteogenetic dif-
ferentiation and mineralization. 
2. Materials and methods 
2.1. Material preparation and isolation 
Whole plants of Lycopodium obscurum L. were col-
lected from Jianshi County, Hubei Province, China. 
Plants were first air-dried and then ground to fine pow-
der. Samples then underwent a MeOH extraction three 
times at room temperature. The MeOH extract was 
resuspended in 3% tartaric acid/H2O (pH=3) and then 
partitioned with ethyl acetate (EtOAc). The EtOAc 
extract was resuspended in 90% H2O/MeOH and then 
successively partitioned with petroleum ether (PE), 
EtOAc and n-BuOH. The EtOAc extract was subjected 
to column chromatography (CC) (silica gel, 
PE/Acetone 9:1, 8:2, 7:3, 1:1, 3:7, 0:1, v/v) to give 9 
fractions (Fr.1−Fr.9). Fr.2 was subjected to CC (silica 
gel, cyclohexane/acetone 1:0 → 1:1) to give compound 
A. 
2.2. Nuclear Magnetic Resonance 
Nuclear Magnetic Resonance (NMR) spectra analy-
sis was performed to identify the structure of com-
pound A. Spectra runs were performed on a Bruker 
AM-400 spectrometer with TMS as internal standard. 
Electron ionized mass spectrometry (EIMS) and high 
resolution EIMS were measured via a Finnigan MAT 
95 instrument.  
Compound A: white amorphous powder, C29H48O3 
[α] D = +53.0 (c=0.965, C5H5N) 1H NMR (400 MHz, 
C5D5N)  and  13C-NMR (100 MHz, C5D5N) as  
shown in Table 1; HR EIMS m/z 444.3593 (calcd for 
C29H48O3, 444.3604)，EI MS: m/z  444 (M+ , 33)，
426 (30)，411 (5)，398 (5), 332 (4)，271 (8)，246 (23)，
231 (100)，163 (13)，121 (12)，107 (12)，95 (15)，
81 (14)，55 (10). Therefore, compound A was identified 
as stigmastane-3-oxo-21-oic acid (SA) (Figure 1). 
A stock solution of 16 mM SA was made by dis-
solving SA in DMSO with vortexing and heated to 
60oC for 30 minutes. The stock solution was kept at 
-20oC until use. Pure DMSO was used as control (0 
μM).  
2.1. Cell culture medium 
For cell expansion, Mouse osteoblastic MC3T3-E1 
subclone 14 were cultured in growth medium (α-MEM 
supplemented with 10% fetal bovine serum, 100 U/mL 
of penicillin, and 100 mg/mL streptomycin).  
For the ALP activity assay, Alizarin red mineraliza-
tion assay, and mRNA expression of osteogenic related 
genes, a differentiation medium (growth medium sup-
plemented with 50 μg/mL of ascorbic acid and 10 mM 
glycerophosphate and 10-8 M of dexamethasone) was 
used for the duration of the experiment. 
 
Figure 1. Molecular structure of SA 
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2.2. Cell viability assay 
Any potential toxic effect of SA upon cell viability 
was assessed via an Alamar Blue assay. MC3T3-E1 
cells were seeded at a density of 1x103 cells/well in 
150 µL growth media in opaque 96-well plates (Nunc). 
After 1 day culture, media was removed from the 96 
well plate and cells were treated with a dose of SA (1, 2, 
4, 8, 16 µM in differentation medium) for 3 days (n = 3 
wells per dose). Then 18 µL of Alamar Blue reagent 
(Invitrogen) was added to the medium to create a final 
concentration of 10% v/v and the plates were incubated 
@37°C for a period of 4-5 hours. After incubation, flu-
orescence (excitation @544 nm, emission @590 nm) 
was measured using a fluorescence plate reader (BMG 
PolarStar Optima), all samples were run in triplicates. 
The fold-change of cell numbers based on metabolic 
activity was calculated for each time point. Differentia-
tion medium with 1% DMSO was used as an 
osteogenic control, (SA concentration 0 µm). Statistical 
difference of test groups vs control was measured via 
ANOVA were p < 0.05 was considered a significant 
difference. 
2.3. Alkaline phosphatase activity assay 
Alkaline phosphatase (ALP) activity was used as 
method for measuring osteogenesis. MC3T3-E1 cell 
were seeded into wells in 6-well plates at a density of 
3x104 cells/well (n = 3 wells per dose). Differentiation 
medium (2 mL) was added to each well and the medi-
um was changed once a week. After cell attachment, 
cells were treated with SA of different concentration (8 
μM and 16 μM). Differentiation medium with 1% 
DMSO (SA concentration 0 µm) was used as an 
osteogenic control. At 8 days and 16 days of treatment, 
medium was aspirated off and the cells were washed 2 
times with PBS. The samples were then incubated with 
1 ml of 0.1% Triton X100 in 0.2 M Tris-HCl at -20oC 
for 10 min. Samples were harvested with a cell scraper 
and were transferred to 1.5 ml Eppendorf tubes. Then, 
they were centrifuged at 10,000 rpm for 10 min at 4oC. 
Each supernatant (100 μL) was transferred into wells in 
96-well microplate. para-Nitrophenylphosphate (pNPP) 
substrate solution (200 μL) was added to each well and 
the plate was incubated in dark for 30 min at room 
temperature with gentle shaking. After the incubation, 
the plate was read @405 nm in a multi-well plate read-
Table 1. 
No. 1H-NMR -NMR No. 1H-NMR -NMR 
1 
1.60 (1H, m) 
38.7 15 1.59 (2H, m) 24.4 
2.28 (1H, m) 
2 
1.73 (1H, m) 
38.5 16 1.51 (2H, m) 28.4 
2.11 (1H, m) 
3 ---- 210.8 17 1.01 (1H, m) 56.4 
4 
2.10 (1H, m) 
45.2 18 0.99 (3H, s) 12.3 
2.24 (1H, m) 
5 1.34 (1H, m) 47.1 19 0.88 (3H, s) 11.7 
6 1.66 (2H, m) 29.4 20 1.18 (1H, m) 46.0 
7 
0.81 (1H, m) 
32.3 21 ---- 178.1 
1.58 (1H, m) 
8 1.32 (1H, m) 35.9 22 1.60 (1H, m) 31.0 
   
 1.86 (1H, m)  
9 1.88 (1H, m) 53.6 23 1.35 (1H, m) 28.0 
   
 1.95 (1H, m)  
10 ---- 36.1 24 2.55 (1H, m) 49.1 
11 1.37 (2H, m) 21.9 25 1.21 (1H, m) 29.8 
12 1.07 (1H, m) 39.0 
26 0.84 (3H, d, J = 
6.6Hz) 
20.4 
 
13 
1.70 (1H, m) 
 
43.1 
 
27 
 
0.84 (3H, d, J = 
6.6Hz) 
 
19.5 ---- 
14 0.59 (1H, m) 54.3 28 1.33 (2H, m) 23.6 
   
29 0.92 (3H, m) 12.8 
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er (n = 3). Statistical difference of test groups vs con-
trol was measured via ANOVA were p < 0.05 was con-
sidered a significant difference. 
2.4. Alizarin red S staining 
Alizarin red S staining was used as a method for as-
sessing cell mineralization. MC3T3-E1 cells were 
seeded into wells of 48-well plates at a density of 7.5 x 
103 cells/well and cultured with differentiation medium 
supplemented with 2 different concentrations of SA (8 
μM and 16 μM). To determine matrix mineralization, at 
8 days and 16 days treatment, triplicate samples were 
washed twice with PBS and fixed with ice cold metha-
nol (-20°C) for 10 minutes at room temperature. They 
were then washed twice with dH2O and incubate with 1% 
Alizarin red S (Sigma-Aldrich). After aspiration of the 
unincorporated dye, samples are washed several times 
with dH2O and air-dried. Stained monolayers were 
photographed with inverted phase microscopy. To 
quantify the amount of mineralization, acetic acid (800 
μL 10% v/v) was added to each well, and the plate in-
cubated at room temperature for 30 minutes with shak-
ing. The monolayers were scraped from the plate with a 
cell scraper and transferred in 10% acetic acid to a 1.5 
mL microcentrifuge tube. After vortexing for 30 se-
conds, the slurry was overlaid with 200-300 μL mineral 
oil (Sigma-Aldrich), heated to 85oC for 10 minutes, 
and transferred to ice for 5 minutes. Then, the slurry 
was centrifuged at 20,000 g for 15 minutes and 
300-400 μL of each supernatant was removed to a new 
1.5 mL microcentrifuge tube. Ammonium hydroxide 
(200 μL, 10% v/v) was added to neutralize the acid. 
Aborption of 150 μL of the supernatant at 405 nm in 
96-well normal plates (Nunc) (n = 3). Statistical dif-
ference of test groups vs control was measured via 
ANOVA were p < 0.05 was considered a significant 
difference. 
2.5. Evaluation of mRNA expression 
Cells were seeded into 48-well plates at a density of 
7.5 x 103 cells/well and cultured with differentiation 
medium containing SA at either 8 μM or 16 μM final 
concentrations, for 8 or 16 days (n = 3). At respective 
time points the cells were harvested in TRIzol (Life 
Techologies, Australia) and total RNA isolated follow-
ing the manufacturer’s instructions. The first strand of 
cDNA was synthesized using a SuperScript™ III 
First-Strand Synthesis SuperMix kit (Life Techologies). 
Real-time PCR was performed using Brilliant SYBR 
Green Master Mix (Life Techologies). Real-time PCR 
primers (GeneWorks, TheBarton, SA, Australia) were 
the same as those described earlier in Table 1. [16]. 
The RT-qPCR assays were performed in a 384 well 
format, using an Eppendorf epMotion 5075 robot for 
liquid transfers, and a 7900HT Fast Real-time system 
(Applied Biosystems) was used for the thermal cycling. 
The PCR cycling parameters were as follows: enzyme 
activation step: 95oC for 10 min; denaturing: 95oC for 
15 s; annealing and extension: 60oC for 60 s; number of 
cycles: 45. PCR reactions for all samples were run in 
triplicate and the data was collected with software of 
Applied Biosystems SDS 2.2.2 and analyzed using the 
2-ΔΔCt method (Livak and Schmittgen 2001). GAPDH 
was used as a control gene. Statistical difference of fold 
change was measured via ANOVA with a post hoc test 
were p < 0.05 was considered a significant difference. 
3. Results and discussion 
3.1. The effect of SA on osteoblast pro-
liferation 
As detected by the Alamar blue, assay, SA had no 
detectable effect upon the metabolic activity of MC3T3 
cells at any of the five tested concentration, up to 3 
days, as shown in Figure 2. Following these results, the 
two highest concentrations of SA (8 µm and 16 µm) 
were used for all subsequent experiments. 
3.2. The effect of SA on alkaline phos-
phatase activity 
As shown in Figure 3A, after 8 days of treatment, 
both tested concentrations of SA had a significant ef-
fect of inhibiting alkaline phosphatase activity when 
compared to the control. However, by 16 days incuba-
tion, the alkaline phosphatase activity for both SA 
concentrations had been restored to control levels. 
Figure 2. Alamar blue cell metabolic activity assay for 
assessing any toxic effect that SA has on MC3T3s. Error 
bars displayed are 1 SD (n=3). 
 
0
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500
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Fluorescence
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3.3. The effect of SA on bone matrix 
mineralization 
Alizarin red S was used as a semi-quantification of 
bone matrix mineralization. As shown in Figure 3B, 
mineralization of the matrix was significantly higher 
than control at 16 days time point.  
Quantitative results; shown in Figure 4, indicated 
that after 16 days treatment cells treated with SA at 
both tested concentrations had a significantly enhanced 
level of mineralization when compared to the untreated 
control. 
3.4. The effect of SA on gene expres-
sion 
Real time PCR was used to analysis key osteogenic 
gene expression, and results summarized in Figure 5. 
and Table 2. Real-time PCR data revealed that 
short-term treatment with SA had an inhibitory effect 
on ALP mRNA expression although the down regula-
tion observed from the 16 µM SA dose was not consid-
ered to be statistically significant (Figure 5A). After 16 
days the treatment of 8 μM SA, had a significant up 
regulatory effect of ALP expression. In contrast the 16 
μM SA treatment had a significant down regulation 
effect of ALP expression.  
Short-term treatment (8 days) of SA had an inhibito-
ry effect of COL1 expression at both test concentra-
tions (Figure 5B), whereas long-term treatment (16 
days) did not have a significant effect on expression.  
OPN expression was significantly enhanced by both 
concentrations of SA after 8 days treatment, whereas 
SA only at 16 µM stimulated OPN expression at the 16 
days treatment time point (Figure 5C). The expression 
of IBSP mRNA was inhibited by the 16 µm SA treat-
ment at 8 days, while there was as inhibitory trend with 
the 8 µm concentration this was not statistically signif-
icant. An inhibitory effect was observed at 16 days by 
both concentrations (Figure 5D). For OCN, SA treat-
ment at of both concentrations at 8 days stimulated 
mRNA expression (Figure 5E); Expression was unaf-
fected at 16 days for either concentration. The mRNA 
expression of BMP2 (shown in Figure 5F) was unaf-
fected. 
Runx2 and OTX are two key genes expressed by 
osteoprogeniter cell during differentiation to osteo-
blasts. In our study, only the 8 µM concentration at the 
16 day time point had a significant up-regulatroy effect 
upon Runx2 expression, although at the 8 day time the 
effect was inhibtaory (Figure 5G). There was slight 
inhibitory effect on Runx2 mRNA expression at 16 µM 
SA concentration at day 16, and a trend at day 8, alt-
hough this was not significant. OTX expression, on the 
other hand, was inhibited by both SA concentrations at 
both time points (Figure 5H). As for c-jun, there was a 
near three-fold increased mRNA at day 8 with 16 µM 
SA, but a reduction in expression at 16 days (shown in 
Figure 5I); the 8μm concentration had no noticeable 
effect upon regulation. 
 
Figure 4. Quantification of mineralization of osteoblasts 
treated with SA of different concentrations. Error bars 
displayed are 1 SD (n = 3). Significance from the control 
(0 µm) is highlighted by *(p > 0.05). 
0
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*
 
 
Figure 3. A: The effect of SA on Alkaline Phosphatase 
activity of M3T3C cells. Error bars displayed are 1 SD (n 
=3 ). Significance from the control is highlighted by * 
(p > 0.05). B: Photograph of the effect of SA on M3T3C 
mineralization as detected by Alizarin red.  
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SA treatment did not affect c-fos mRNA expression 
at either concentrations or time points (Figure 5J). The 
expression of Jun-D and Fra-2 showed very similar 
patterns: the mRNA expression was reduced by the 8 
μm dosage at day 8, but was significantly enhanced 
after 16 days (Figure 5K and 5M) although Jun-D dis-
played significant up regulation at 8 days with the 16 
μm, it was not as pronounced as the 16 day time point. 
SA treatment at 16 µM resulted in significantly en-
hanced Fra-1 mRNA expression at 8 and 16 days; but at 
the 16 day time point 8 µM SA concentration the ex-
pression of Fra-1 was indistinguishable from the con-
trol, while the at 8 days up regulation was observed 
(Figure 5L).  
4. Discussion 
With the development of molecular biology and 
pharmacology and the opening of China to the rest of 
the world, traditional Chinese herbal medicine has at-
tracted much research interest and could provide poten-
tial solutions to some serious diseases currently affect-
ing the world population. Lycopodium obscurum L. has 
been used in traditional Chinese herbal medicine and 
traditional Tu Nationality herbal medicine for many 
centuries; primarily for healing contusion and bone 
fractures in some ethnic groups in China. However, 
little detail is known about the biological mechanism of 
the therapies. In order to understand more about this 
traditional Chinese herbal medicine, we investigated 
the effect an extract of one of the compounds, 
stigmastane-3-oxo-21-oic acid (SA) from plant 
Lycopodium obscurum L had upon osteogenic activity 
of M3T3C cells. 
Our initial investigation showed that SA has no no-
ticeable toxic effect upon the M3T3Cs up to the maxi-
mum tested concentration of 16 μm, as measured by the 
MTT assay. When looking at mineralization by staining 
with Alizarin red increased mineralization was ob-
served, however the effect of the test dosages of SA on 
ALP activity actually caused a decrease in observed 
activity on M3T3C cells. 
In this study, the expression of Osterix was generally 
down-regulated by the supplementation of SA to the 
media. Runx2 was down regulated at day 8, but up 
regulated at day 16; this suggests that SA is not pro-
moting the early stages of differentiation of 
mesenchymal stem cells toward osteoblasts lineage.  
Table 2. 
  
SA concentration Gene Expression change 
 
  SA concentration Gene Expression change 
Day 8 8 µm 
ALP 
↓ 
 Day 8 
8 µm 
Osterix  
↓ 
16 µm − 
 
16 µm ↓ 
Day 16 8 µm ↑  Day 16 
8 µm ↓ 
16 µm ↓ 
 
16 µm ↓ 
Day 8 8 µm 
COL1 
↓ 
 Day 8 
8 µm 
C-Jun 
− 
16 µm ↓ 
 
16 µm ↑ 
Day 16 8 µm −  Day 16 
8 µm − 
16 µm − 
 
16 µm ↓ 
Day 8 8 µm 
OPN 
↑ 
 Day 8 
8 µm 
C-Fos  
− 
16 µm ↑ 
 
16 µm − 
Day 16 8 µm −  Day 16 
8 µm − 
16 µm ↑ 
 
16 µm − 
Day 8 8 µm 
ISBP 
− 
 Day 8 
8 µm 
Jun-D 
↓ 
16 µm ↓ 
 
16 µm − 
Day 16  8 µm ↓  Day 16 
8 µm ↑ 
16 µm  ↓ 
 
16 µm ↑ 
Day 8 8 µm 
OCN 
↑ 
 Day 8 
8 µm 
Fra-1 
↑ 
16 µm ↑ 
 
16 µm ↑ 
Day 16 8 µm −  Day 16 
8 µm − 
16 µm − 
 
16 µm ↑ 
Day 8 8 µm 
BMP-2 
− 
 Day 8 
8 µm 
Fra-2 
↑ 
16 µm − 
 
16 µm ↓ 
Day 16 8 µm −  Day 16 
8 µm ↑ 
16 µm − 
 
16 µm ↑ 
Day 8 8 µm 
Runx-2 
− 
     16 µm ↓ 
     
Day 16 8 µm ↑         
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Figure 5. mRNA expression of bone-related genes (A-F), early osteogenic differentiation genes (G-H) and mineralization stage 
(I-M) after culture with SA (8 µM and 16 µM) after 8 or 16 days. Error bars displayed are 1 SD (n = 3). Significance from the 
control (0 µm) is highlighted by *(p > 0.05). 
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As previously stated, SA treatment of both test 
cconcentrations had an inhibitory effect upon ALP ac-
tivity at the 8 day time point, and this result matches 
the rtPCR trend of ALP expression. In addition, our 
data revealed that COL1 mRNA expression was signif-
icantly inhibited at the 8 day time point of SA treatment, 
although normal expression levels were returned at the 
16 day time point. These results suggest that SA treat-
ment may cause a delay in short term bone matrix for-
mation but not the late stage. Since ALP and COL1 are 
two bone-related genes highly expressed in the early 
stages of bone matrix formation, our data on ALP and 
COL1 mRNA expression suggests that SA does not 
promote this early stage bone matrix formation, and 
may even have an inhibitory function. Therefore, from 
the above result, we may hypothesis that, if SA exerts a 
positive effect on osteogenesis, it may do this by 
up-regulating bone matrix mineralization, as opposed 
to  preosteoblast differentiation and bone matrix for-
mation. 
This hypothesis is supported by the effect SA has 
upon OCN expression; where it promotes upregulation 
at the 8 day time point, and the mineralization assay 
showing increased levels of matrix mineralization. 
OCN, which was at some stage thought to be the only 
bone-specific gene, is strongly related to calcium ion 
binding to the bone matrix and is believed to be the 
marker of bone mineralization. It is expressed highly in 
the stages of bone mineralization [17]. In our study, 
OCN mRNA expression was enhanced after short-term 
treatment (8 days) of osteoblasts with both concentra-
tions, which suggested that SA could enhance early 
stage bone mineralization. Meanwhile, our Alizarin 
Red S staining assay result further confirmed that in 
vitro mineralization level in SA treated samples was 
significantly higher than control after 16 days.  
Another gene, OPN mRNAs expression was gener-
ally enhanced in the early time point by SA treatment. 
OPN is strongly associated with calcium or hydroxy-
apatite binding in bone mineralization [18-19] and bone 
remodeling [20], therefore, this result further suggests 
that SA treatment is havening a significant enhancing 
effect upon bone mineralization and remodeling. Since 
remodeling is a necessary step in bone fracture healing, 
the enhancive effect of SA in fracture healing may in-
volve the stimulation of remodeling on bone fracture 
interface.  
Jun (c-Jun, JunB, JunD) and fos (c-fos, Fra-1, Fra-2 
etc.) proteins are the components of transcription factor 
AP-1. AP-1 is a heterodynamic protein which plays a 
key role in modulating several gene expressions in-
cluding the process of osteogenesis and remodeling 
[21]. It has been demonstrated that some of these genes’ 
expression is highly differentiation stage-regulated. In 
the early stage of differentiation, fos and Jun are highly 
expressed. After extracellular matrix formation and 
mineralization, their expression declines and Fra-2 and 
JunD become the major components of the AP-1 com-
plex [22] In our study, both Jun-D and Fra-2 mRNA 
expression was significantly enhanced at the 16 day 
time point of treatment with SA of both concentration 
when compared with control while c-fos expression 
was not affected by SA treatment. These findings fur-
ther suggest that osteoblast mineralization could be 
stimulated by SA treatment. The early stage enhanced 
expression of Fra-1 is also helpful to osteoblast matu-
ration and mineralization in this study [23]. 
Therefore, we may conclude that SA treatment may 
be favorable for the bone development and bone frac-
ture healing, with a potential mechanism of stimulating 
bone matrix mineralization and bone fracture interface 
remodeling. 
However, our result showed that SA treatment was 
not favorable for bone sialoprotein expression, alt-
hough other results suggest that SA stimulates bone 
mineralization. As a major extracellular bone matrix 
protein, bone sialoprotein is responsible for the nuclea-
tion of HA crystal [24] and mineralization in bone and 
cementum [25-26]. Further studies are needed to ex-
plore the mechanism.  
5. ACKNOWLEDGEMENTS  
The authors thank Special Basic Research Foundation for Central 
Government-funded Universities for supporting this research, along 
with the Australian Research Council (ARC) and the Endeavour 
awards for a scholarship for Chaoyuan Wang. 
 
REFERENCES  
[1] Fang ZX, Liao CL. 2006, A survey of medicinal plants of 
Enshi, Hubei Province. Wuhan: Hubei Science and 
Technology Press, 31 
[2] Yongfei G, Hui H. 2003, An observation of the general 
therapeutic effect of bone fracture resulted from osteo-
porosis. Guangxi Medical Journal, 25(112): 2520-2521 
[3] Weihong H, Shaoji H. 2000, Examples of Yang He Tang 
in curing bone injury. Fujian Journal of Traditional Chi-
nese Medicine. 31(5):47-48.  
[4] Cuicui Teng, et al. 2008, Research Advancement about 
Chemical Composition and Pharmacological Actions of 
Lycooodium Japanicum Thunb. Medical Recapitulate. 
14(20):3174-3175 
[5] Xiao-Li Li, Yu Zhao, Xiao Cheng, Lin Tu, Li-Yan Peng, 
Gang Xu, Qin-Shi Zhao. 2006, Japonicumins A. D.: Four 
Chaoyuan Wang et al. / Natural Science * (2012) **-** 
Copyright © 2012 SciRes.                                    Openly accessible at http://www.scirp.org/journal/ns/ 
new compounds from Lycopodiam japonicum. Helv 
Chim Acta. 89(7):1467-1473 
http://dx.doi.org/10.1002/hlca.200690148 
[6] Jian Yan, Xiang-Ming Zhang, Zhong-Rong Li, Lin Zhou, 
Jian-Chao Chen, Li-Rong Sun, Ming-Hua Qiu. 2005, 
Three new triterpenoids from Lycopodium japonicum 
THUNB. Helv Chim Acta. 88(2):240-244 
http://dx.doi.org/10.1002/hlca.200590004 
[7] Ying-Hong Zhao, Tie-Zhong Deng, Yu Chen, 
Xiang-Ming Liu & Guang-Zhong Yang. 2010, Two new 
triterpenoids from Lycopodium obscurum L. Journal of 
Asian Natural Products Research. 12(8):666-671 
http://dx.doi.org/10.1080/10286020.2010.493881 
PMid:20706902  
[8] Fisher, L.W., Termine, J.D. 1985, Noncollagenous pro-
teins influencing the local mechanisms of calcification. 
Clin Orthop, 200:362-385 
PMid:3905122  
[9] S Mundlos, F Otto, C Mundlos, J.B Mulliken, A.S 
Aylsworth, S Albright, D Lindhout, W.G Cole, W Henn, 
J.H.M Knoll, M.J Owen, R Mertelsmann, B.U Zabel, 
B.R Olsen. 1997, Mutations involving the transcription 
factor CBFA1 cause cleidocranial dysplasia. Cell. 
89(5):773-779 
http://dx.doi.org/10.1016/S0092-8674(00)80260-3  
[10] Sun Dong Mei, Liu Zhong-Bo, Zhao Yan, Gong 
Zhen-Wei, Li Dan, Wang Xi-Yuan, Zeng Xian Lu, Liu 
Wen-Guang. 2006, Runx2 is Involved in regulating os-
terix promoter activity and gene expression. Progress in 
Biochemistry and Biophysics. 33(10):957-964  
[11] Kazuhisa Nakashima, Xin Zhou, Gary Kunkel, Zhaoping 
Zhang, Jian Min Deng, Richard R. Behringer, Benoit de 
Crombrugghe. 2002, The novel zinc finger-containing 
transcription factor osterix is required for osteoblast dif-
ferentiation and bone formation. Cell. 108(1):17-29 
http://dx.doi.org/10.1016/S0092-8674(01)00622-5  
[12] Yoshio Ohyama, Akira Nifuji, Yukiko Maeda, Teruo 
Amagasa, Masaki Noda. 2004, Spaciotempora associa-
tion and bone morphogenetic protein regulation of sele-
rostin and ostetix expression during embryonic esteo-
genesis. Endocrinology. 10 (145):4685-4692 
http://dx.doi.org/10.1210/en.2003-1492 
PMid:15217980  
[13] Thomas A. Owen, Michael Aronow, Victoria Shalhoub, 
Leesa M. Barone, Laurens Wilming, Melissa S. Tassi-
nari, Mary Beth Kennedy, Shirwin Pockwinse, Jane B. 
Lian, Gary S. Stein. 1990, Progressive development of 
the rat osteoblast phenotype in vitro: reciprocal relation-
ships in expression of genes associated with osteoblast 
proliferation and differentiation during formation of the 
bone extracellular matrix. J Cell Physiol. 143:420-430 
http://dx.doi.org/10.1002/jcp.1041430304 
PMid:1694181  
[14] Shirwin M. Pockwinse, Laurens G. Wilming, Donna M. 
Conlon, Gary S. Stein, Jane B. Lian. 1992, Expression of 
cell growth and bone specific genes at single cell resolu-
tion during development of bone tissue-like organization 
in primary osteoblast cultures. J Cell Biochem. 
49:310-323. 
http://dx.doi.org/10.1002/jcb.240490315 
PMid:1644867  
[15] Fallon MD, Whyte MP, Teitelbaum SL.. 1980, Stereo-
specific inhibition of alkaline phosphatase by 
L-tetramisole prevents cartilage calcification. Lab Invest. 
43:489-494 
PMid:6449630  
[16] Su-Ui Leea, c, Sang-Joon Parkb, Han Bok Kwakd, Jae-
min Ohd, Yong Ki Mina, Seong Hwan Kima,. 2008, 
Anabolic activity of ursolic acid in bone: Stimulating os-
teoblast differentiation in vitro and inducing new bone 
formation in vivo. Pharmacological Research 58:290-296 
http://dx.doi.org/10.1016/j.phrs.2008.08.008 
PMid:18822379  
[17] Stein GS, et al. 1992, Mechanisms regulating osteoblast 
proliferation and differentiation. Editors: Bilezikian JP, 
Raisz LG, Rodan GA. In: Principle of bone biology. 
Academic press p71. 
PMid:1552467  
[18] A Oldberg, A Franzén, and D Heinegård. 1986, Cloning 
and sequence analysis of rat bone sialoprotein (osteopon-
tin) cDNA reveals an Arg-Gly-Asp cell-binding se-
quence. Proc Natl Acad Sci U S A. 83(23):8819-8823. 
http://dx.doi.org/10.1073/pnas.83.23.8819 
PMid:3024151 PMCid:387024 
[19] C W Prince, T Oosawa, W T Butler, M Tomana, A S 
Bhown, M Bhown and R E Schrohenloher. 1987, Isola-
tion, characterization, and biosynthesis of a phosphory-
lated glycoprotein from rat bone. J Biol Chem. 
262(6):2900-2907. 
PMid:3469201 
[20] F P Reinholt, K Hultenby, A Oldberg, and D Heinegård. 
1990, Osteopontin--a possible anchor of osteoclasts to 
bone. Proc Natl Acad Sci USA. 87(12):4473-4475 
http://dx.doi.org/10.1073/pnas.87.12.4473 
PMid:1693772 PMCid:54137  
[21] Wagner EF. 2002, Functions of AP-1 (fos/Jun) in bone 
development. Ann Rheum Dis 61(Suppl II):ii40-42 
PMid:12379619 PMCid:1766713  
[22] L R McCabe, C Banerjee, R Kundu, R J Harrison, P R 
Dobner, J L Stein, J B Lian and G S Stein. 1996, Devel-
opmental expression and acticities of specific fos and jun 
proteins are functionally related to osteoblast maturation: 
role of Fra-2 and JunD during differentiation. Endocri-
nology. 137:4398-4408 
http://dx.doi.org/10.1210/en.137.10.4398 
PMid:8828501 
[23] G. Sabatakos N. A. Sims J. Chen K. Aoki M. B. Kelz M. 
Amling Y. Bouali K. Mukhopadhyay K. Ford E. J. 
Nestler & R. Baron 2000, Increased bone formation and 
osteosclerosis in mice overexpressing the transcription 
Vol.*, No.*, **-** (2012)                                                                       Natural Science 
doi:10.4236/ns.2012.***** 
Copyright © 2012 SciRes.                                    Openly accessible at http://www.scirp.org/journal/ns/ 
[24] factor Fra-1. Nat Med. 6:985-990 
http://dx.doi.org/10.1038/79683 
PMid:10973317 
[25] Ake Oldberg, AhndersF ranzen, and Dick Heinegkd. 
1988, The primary structure of a cell-binding bone sialo-
protein. J Biol Chem. 263:19430-19432 
PMid:3198635 
[26] Jinkun Chen, Howard S. Shapiro, Jaro Sodek. 1992, De-
velopment expression of bone sialoprotein mRNA in rat 
mineralized connective tissues. J Bone Miner Res. 
7:987-997. 
http://dx.doi.org/10.1002/jbmr.5650070816 
PMid:1442213 
[27] Luc Malaval, Fina Liu, Patricia Roche, Jane E. Aubin. 
1999, Kinetics of osteoprogenitor proliferation and os-
teoblast differentiation in vitro. J Cell Biochem. 74:16-27 
http://dx.doi.org/10.1002/(SICI)1097-4644(19990915)74
:4<616::AID-JCB11>3.0.CO;2-Q 
 
 
